يعرض 1 - 10 نتائج من 19 نتيجة بحث عن '"Everolimus/adverse effects"', وقت الاستعلام: 1.71s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Everolimus-Eluting Stents or Bypass Surgery for Multivessel Coronary Artery Disease: Extended Follow-Up Outcomes of Multicenter Randomized Controlled BEST Trial

    المساهمون: Damras Tresukosol, Woong Chol Kang, Hyuck Moon Kwon, Seung-Woon Rha, Do-Sun Lim, Myung-Ho Jeong, Bong-Ki Lee, He Huang, Young Hyo Lim, Jang Ho Bae, Byung Ok Kim, Tiong Kiam Ong, Sung Gyun Ahn, Cheol-Hyun Chung, Duk-Woo Park, Seung-Jung Park, Kwon, Hyuck Moon

    مصطلحات موضوعية: Coronary Artery Disease* / diagnostic imaging, Coronary Artery Disease* / surgery, Drug-Eluting Stents* / adverse effects, Everolimus / adverse effects, Follow-Up Studies, Humans, Myocardial Infarction* / epidemiology, Myocardial Infarction* / etiology, Percutaneous Coronary Intervention* / adverse effects, Prospective Studies, Treatment Outcome, coronary artery bypass, coronary artery disease, percutaneous coronary intervention, stents

    العلاقة: CIRCULATION; J00533; OAK-2022-10607; https://ir.ymlib.yonsei.ac.kr/handle/22282913/194502Test; T9992023160; CIRCULATION, Vol.146(21) : 1581-1590, 2022-11

    الإتاحة: https://doi.org/10.1161/CIRCULATIONAHA.122.062188Test
    https://ir.ymlib.yonsei.ac.kr/handle/22282913/194502Test

    View record in BASE النص الكامل

    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial

    المساهمون: Sumanta K Pal, Javier Puente, Daniel Y C Heng, Hilary Glen, Piotr Koralewski, Daniil Stroyakovskiy, Boris Alekseev, Francis Parnis, Daniel Castellano, Tudor Ciuleanu, Jae Lyun Lee, Kaisa Sunela, Karen O'Hara, Terri A Binder, Lixian Peng, Alan D Smith, Sun Young Rha, Rha, Sun Young

    مصطلحات موضوعية: Antineoplastic Combined Chemotherapy Protocols / adverse effects, Carcinoma, Renal Cell* / pathology, Everolimus / adverse effects, Humans, Kidney Neoplasms* / pathology, Phenylurea Compounds, Quinolines, Vascular Endothelial Growth Factor A, Efficacy, Lenvatinib plus everolimus, Phase 2 trial, Renal cell carcinoma, Safety, Starting dose

    العلاقة: EUROPEAN UROLOGY; J00854; OAK-2022-07619; https://ir.ymlib.yonsei.ac.kr/handle/22282913/192006Test; T202205128; EUROPEAN UROLOGY, Vol.82(3) : 283-292, 2022-09

    الإتاحة: https://doi.org/10.1016/j.eururo.2021.12.024Test
    https://ir.ymlib.yonsei.ac.kr/handle/22282913/192006Test

    View record in BASE

    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    Efficacy, Retention and Tolerability of Everolimus in Patients with Tuberous Sclerosis Complex: A Survey-Based Study on Patients’ Perspectives

    المؤلفون: Willems, Laurent M., Rosenow, Felix, Schubert-Bast, Susanne, Kurlemann, Gerhard, Zöllner, Johann Philipp, Bast, Thomas, Bertsche, Astrid, Bettendorf, Ulrich, Ebrahimi-Fakhari, Daniel, Grau, Janina, Hahn, Andreas, Hartmann, Hans, Hertzberg, Christoph, Hornemann, Frauke, Immisch, Ilka, Jacobs, Julia, Klein, Karl Martin, Klotz, Kerstin A., Kluger, Gerhard, Knake, Susanne, Knuf, Markus, Marquard, Klaus, Mayer, Thomas, Meyer, Sascha, Muhle, Hiltrud, Müller-Schlüter, Karen, von Podewils, Felix, Ruf, Susanne, Sauter, Matthias, Schäfer, Hannah, Schlump, Jan-Ulrich, Syrbe, Steffen, Thiels, Charlotte, Trollmann, Regina, Wiemer-Kruel, Adelheid, Wilken, Bernd, Zukunft, Bianca, Strzelczyk, Adam

    المصدر: http://lobid.org/resources/99370678146406441Test#!, 35(10):1107-1122.

    مصطلحات موضوعية: Neurology, Surveys and Questionnaires [MeSH], Aged [MeSH], Psychopharmacology, Germany/epidemiology [MeSH], Infant [MeSH], Male [MeSH], Patient Preference [MeSH], Original Research Article, Tuberous Sclerosis/diagnosis [MeSH], Child [MeSH], Medication Adherence [MeSH], Pharmacotherapy, Adolescent [MeSH], Fatigue/chemically induced [MeSH], Female [MeSH], Tuberous Sclerosis/drug therapy [MeSH], Adult [MeSH], Humans [MeSH], Treatment Outcome [MeSH], Middle Aged [MeSH], Tuberous Sclerosis/epidemiology [MeSH], Everolimus/adverse effects [MeSH], Psychiatry, Young Adult [MeSH], Immunosuppressive Agents/therapeutic use [MeSH], Neurosciences, Immunosuppressive Agents/adverse effects [MeSH], Child, Preschool [MeSH]

    العلاقة: https://repository.publisso.de/resource/frl:6464955Test; https://doi.org/10.1007/s40263-021-00839-4Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478774Test/

    الإتاحة: https://doi.org/10.1007/s40263-021-00839-4Test
    https://repository.publisso.de/resource/frl:6464955Test
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478774Test/

    View record in BASE

    أضف إلى المفضلة
  4. 4
    دورية أكاديمية
    Efficacy and Safety of Everolimus With Reduced Tacrolimus in Liver Transplant Recipients: 24-month Results From the Pooled Analysis of 2 Randomized Controlled Trials

    المساهمون: Sung-Gyu Lee, Long-Bin Jeng, Faouzi Saliba, Arvinder Singh Soin, Wei-Chen Lee, Paolo De Simone, Frederik Nevens, Kyung-Suk Suh, Lutz Fischer, Dong Jin Joo, John Fung, Jae-Won Joh, Toshimi Kaido, David Grant, Matthias Meier, Barbara Rauer, Carole Sips, Shuhei Kaneko, Gary Levy, Joo, Dong Jin

    مصطلحات موضوعية: Adult, Calcineurin Inhibitors / administration & dosage, Calcineurin Inhibitors / adverse effects, Carcinoma, Hepatocellular / diagnosis, Hepatocellular / surgery, Drug Therapy, Combination, Everolimus / administration & dosage, Everolimus / adverse effects, Female, Glomerular Filtration Rate / drug effects, Graft Rejection / diagnosis, Graft Rejection / immunology, Graft Rejection / prevention & control, Graft Survival / drug effects, Humans, Immunosuppressive Agents / administration & dosage, Immunosuppressive Agents / adverse effects, Kidney / drug effects, Kidney / physiopathology, Liver Neoplasms / diagnosis, Liver Neoplasms / surgery, Liver Transplantation* / adverse effects, Male, Middle Aged, Randomized Controlled Trials as Topic, Recurrence, Tacrolimus / administration & dosage, Tacrolimus / adverse effects

    العلاقة: TRANSPLANTATION; J02754; OAK-2021-08802; https://ir.ymlib.yonsei.ac.kr/handle/22282913/187238Test; T202105332; TRANSPLANTATION, Vol.105(7) : 1564-1575, 2021-07

    الإتاحة: https://doi.org/10.1097/TP.0000000000003394Test
    https://ir.ymlib.yonsei.ac.kr/handle/22282913/187238Test

    View record in BASE

    أضف إلى المفضلة
  5. 5
    دورية أكاديمية
    Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

    المساهمون: Robert Motzer, Boris Alekseev, Sun-Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E Hutson, Evgeny Kopyltsov, María J Méndez-Vidal, Vadim Kozlov, Anna Alyasova, Sung-Hoo Hong, Anil Kapoor, Teresa Alonso Gordoa, Jaime R Merchan, Eric Winquist, Pablo Maroto, Jeffrey C Goh, Miso Kim, Howard Gurney, Vijay Patel, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Bohuslav Melichar, Frederic Rolland, Ugo De Giorgi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Corina E Dutcus, Alan D Smith, Lea Dutta, Kalgi Mody, Rodolfo F Perini, Dongyuan Xing, Toni K Choueiri, Rha, Sun Young

    مصطلحات موضوعية: Adult, Aged, 80 and over, Antibodies, Monoclonal, Humanized / administration & dosage, Humanized / adverse effects, Antineoplastic Agents / adverse effects, Antineoplastic Agents / therapeutic use, Antineoplastic Combined Chemotherapy Protocols / adverse effects, Antineoplastic Combined Chemotherapy Protocols / therapeutic use, Carcinoma, Renal Cell / drug therapy, Renal Cell / mortality, Everolimus / administration & dosage, Everolimus / adverse effects, Female, Humans, Kidney Neoplasms / drug therapy, Kidney Neoplasms / mortality, Male, Middle Aged, Phenylurea Compounds / administration & dosage, Phenylurea Compounds / adverse effects, Programmed Cell Death 1 Receptor / antagonists & inhibitors, Progression-Free Survival, Protein Kinase Inhibitors / therapeutic use, Quinolines / administration & dosage, Quinolines / adverse effects, Sunitinib / adverse effects

    العلاقة: NEW ENGLAND JOURNAL OF MEDICINE; J02371; OAK-2021-06182; https://ir.ymlib.yonsei.ac.kr/handle/22282913/185460Test; T202104165; NEW ENGLAND JOURNAL OF MEDICINE, Vol.384(14) : 1289-1300, 2021-04

    الإتاحة: https://doi.org/10.1056/NEJMoa2035716Test
    https://ir.ymlib.yonsei.ac.kr/handle/22282913/185460Test

    View record in BASE

    أضف إلى المفضلة
  6. 6
    دورية أكاديمية
    Optical coherence tomography tissue coverage and characterization at six months after implantation of bioresorbable scaffolds versus conventional everolimus eluting stents in the ISAR-Absorb MI trial

    المؤلفون: Rai, Himanshu, Alfonso, Fernando, Maeng, Michael, Bradaric, Christian, Wiebe, Jens, Cuesta, Javier, Christiansen, Evald Høj, Cassese, Salvatore, Hoppmann, Petra, Colleran, Roisin, Harzer, Fiona, Bresha, Jola, Nano, Nejva, Schneider, Simon, Laugwitz, Karl-Ludwig, Joner, Michael, Kastrati, Adnan, Byrne, Robert A

    المصدر: Rai , H , Alfonso , F , Maeng , M , Bradaric , C , Wiebe , J , Cuesta , J , Christiansen , E H , Cassese , S , Hoppmann , P , Colleran , R , Harzer , F , Bresha , J , Nano , N , Schneider , S , Laugwitz , K-L , Joner , M , Kastrati , A & Byrne , R A 2021 , ' Optical coherence tomography tissue coverage and characterization at six months after implantation of bioresorbable scaffolds versus conventional everolimus eluting stents in the ISAR-Absorb ....

    مصطلحات موضوعية: Acute myocardial infarction, Bioresorbable scaffold, Grey-scale signal intensity, Malapposition, Optical coherence tomography, Uncovered struts, BIODEGRADABLE POLYMER, METALLIC STENTS, MYOCARDIAL-INFARCTION, VASCULAR SCAFFOLDS, RANDOMIZED-TRIAL, Percutaneous Coronary Intervention/adverse effects, Predictive Value of Tests, Drug-Eluting Stents, Tomography, Optical Coherence, Humans, Treatment Outcome, Everolimus/adverse effects, Absorbable Implants, Coronary Angiography, Stents

    وصف الملف: application/pdf

    الإتاحة: https://doi.org/10.1007/s10554-021-02251-xTest
    https://pure.au.dk/portal/da/publications/optical-coherence-tomography-tissue-coverage-and-characterization-at-six-months-after-implantation-of-bioresorbable-scaffolds-versus-conventionalTest-everolimus-eluting-stents-in-the-isarabsorb-mi-trial(a6748500-1c1e-4de1-8b08-d744a808f226).html
    https://pure.au.dk/ws/files/274415629/Rai2021_Article_OpticalCoherenceTomographyTiss.pdfTest

    View record in BASE

    أضف إلى المفضلة
  7. 7
    دورية أكاديمية
    Wound healing adverse events in kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor exposure or current standard-of-care: insights from the 24-month TRANSFORM study

    المساهمون: Franco Citterio, Mitchell Henry, Dean Y Kim, Myoung Soo Kim, Duck-Jong Han, Takashi Kenmochi, Eytan Mor, Giuseppe Tisone, Peter Bernhardt, Maria Pilar Hernandez Gutierrez, Yoshihiko Watarai, Kim, Myoung Soo

    مصطلحات موضوعية: Adult, Calcineurin Inhibitors / administration & dosage, Calcineurin Inhibitors / adverse effects, Everolimus / administration & dosage, Everolimus / adverse effects, Female, Humans, Immunosuppressive Agents / administration & dosage, Immunosuppressive Agents / adverse effects, Incidence, Kidney Transplantation, Lymphocele / epidemiology, Lymphocele / etiology, Male, Middle Aged, Mycophenolic Acid / administration & dosage, Mycophenolic Acid / adverse effects, Risk, Surgical Wound Dehiscence / epidemiology, Surgical Wound Dehiscence / etiology, Wound Healing / drug effects, Calcineurin inhibitor, everolimus, randomized, safety, wound healing

    العلاقة: EXPERT OPINION ON DRUG SAFETY; J03925; OAK-2021-05745; https://ir.ymlib.yonsei.ac.kr/handle/22282913/185010Test; T999202325; EXPERT OPINION ON DRUG SAFETY, Vol.19(10) : 1339-1348, 2020-10

    الإتاحة: https://doi.org/10.1080/14740338.2020.1792441Test
    https://ir.ymlib.yonsei.ac.kr/handle/22282913/185010Test

    View record in BASE

    أضف إلى المفضلة
  8. 8
    دورية أكاديمية
    Complex primary percutaneous coronary intervention with ultrathin-strut biodegradable versus thin-strut durable polymer drug-eluting stents in patients with ST-segment elevation myocardial infarction: A subgroup analysis from the BIOSTEMI randomized trial.

    المؤلفون: Iglesias, J.F., Muller, O., Losdat, S., Roffi, M., Kurz, D.J., Weilenmann, D., Kaiser, C., Heg, D., Windecker, S., Pilgrim, T.

    المصدر: Catheterization and cardiovascular interventions, vol. 101, no. 4, pp. 687-700

    مصطلحات موضوعية: Humans, Absorbable Implants, Drug-Eluting Stents, Everolimus/adverse effects, Percutaneous Coronary Intervention/adverse effects, Polymers, Prosthesis Design, Sirolimus/adverse effects, ST Elevation Myocardial Infarction/etiology, Treatment Outcome, Stents, ST-segment elevation myocardial infarction, biodegradable polymer, complex percutaneous coronary intervention, drug-eluting stent, ultrathin-strut

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36807456; info:eu-repo/semantics/altIdentifier/eissn/1522-726X; https://serval.unil.ch/notice/serval:BIB_B2517FD7FFDCTest; urn:issn:1522-1946

    الإتاحة: https://doi.org/10.1002/ccd.30600Test
    https://serval.unil.ch/notice/serval:BIB_B2517FD7FFDCTest

    View record in BASE

    أضف إلى المفضلة
  9. 9
    دورية أكاديمية
    Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea

    المساهمون: College of Medicine, Dept. of Internal Medicine, Kyong Joo Lee, Jae Hee Cho, Sang Hyub Lee, Si Young Song, Kwang Hyuk Lee, Seok Jeong, Ji Kon Ryu, Sang Myung Woo, Seungmin Bang, Jong Kyun Lee, Tae Hoon Lee, Woo Hyun Paik, Yong Tae Kim, Woo Jin Lee, Bang, Seung Min, Song, Si Young

    مصطلحات موضوعية: Adult, Aged, 80 and over, Anemia/chemically induced, Anemia/epidemiology, Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Disease-Free Survival, Everolimus/adverse effects, Everolimus/therapeutic use, Exanthema/chemically induced, Exanthema/epidemiology, Female, Humans, Male, Middle Aged, Neoplasm Grading, Neoplasm Recurrence, Local, Pancreatic Neoplasms/drug therapy, Pancreatic Neoplasms/pathology, Prognosis, Republic of Korea, Retrospective Studies, Stomatitis/chemically induced, Stomatitis/epidemiology, Treatment Outcome, Young Adult, Everolimus, Pancreatic neuroendocrine tumor

    العلاقة: CANCER CHEMOTHERAPY AND PHARMACOLOGY; J00437; OAK-2017-05183; https://ir.ymlib.yonsei.ac.kr/handle/22282913/160894Test; https://link.springer.com/article/10.1007%2Fs00280-017-3421-7Test; T201703544; CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.80(4) : 799-805, 2017

    الإتاحة: https://doi.org/10.1007/s00280-017-3421-7Test
    https://ir.ymlib.yonsei.ac.kr/handle/22282913/160894Test

    View record in BASE

    أضف إلى المفضلة
  10. 10
    دورية أكاديمية
    Everolimus Concentration in Saliva to Predict Stomatitis: A Feasibility Study in Patients with Cancer

    المؤلفون: Laura, Molenaar-Kuijsten, Verheijen, Remy B, Jacobs, Bart A W, Bas, Thijssen, Hilde, Rosing, Dorlo, Thomas P C, Beijnen, Jos H, Neeltje, Steeghs, Huitema, Alwin D R

    المساهمون: Apotheek Opleiding, Apotheek O&O&O, Cancer

    مصطلحات موضوعية: Everolimus/adverse effects, Feasibility Studies, Humans, Neoplasms/drug therapy, Quality of Life, Saliva, Stomatitis/chemically induced, biomarker, everolimus, stomatitis, toxicity, General Medicine, Journal Article

    وصف الملف: application/pdf

    العلاقة: https://dspace.library.uu.nl/handle/1874/445919Test

    الإتاحة: https://dspace.library.uu.nl/handle/1874/445919Test

    View record in BASE

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث